AXXAM

Webinar

“Small modalities, deep impact”: VHH antibodies as complementary approaches for challenging therapeutic targets

Webinar held in collaboration with Isogenica

This webinar is now on demand!
Fill the form below to receive webinar video link directly to your inbox.

    About this webinar:

    Since 2019, small antibodies known as VHHs have been growing rapidly in popularity for diverse therapeutic applications, thanks to a series of FDA approvals for drugs using this modality. 

    VHH antibodies have distinct advantages over traditional antibodies, in terms of stability, simplicity, large-scale production, and target reach.

    A further reason for high levels of interest in this format is that these properties mean that VHHs can be used in infinitely creative ways, through payload targeting, intracellular applications, and building more complex, cutting-edge technologies like targeted protein degradation (TPD).

    Much interest is growing in the potential use of VHH therapeutics against difficult molecular targets, such as GPCRs, as the molecular weight of a VHH and the length of the CDR regions allow them to penetrate the receptor core and access ligand binding pockets and orthosteric/allosteric sites easily.

    In this webinar, Isogenica and Axxam will discuss their newly formed strategic partnership, highlighting the combined strengths of Isogenica’s diverse VHH libraries and Axxam’s expertise in functional assay development and High-Throughput screening platforms. The session will also include examples showcasing the successful application of their respective capabilities.

    What you will learn:

    • What makes VHH antibodies different, and examples of creative therapeutic applications.
    • Successful case studies from Isogenica’s VHH libraries
    • Functional assay development on GPCRs at Axxam

    Keywords:
    VHH, Nanobodies, GPCR, Membrane Receptors, Antibody Discovery, Antibody libraries, Functional assays, High-Throughput Screening.

    Speakers:
    Marion Cubitt – Director of Discovery, Isogenica
    Tommaso Tosi – Principal Scientist Biochemistry, Axxam

    Marion Cubitt is a leading expert on VHH antibodies, and is currently Director of Discovery at Isogenica.

    After completing her PhD in Biochemistry from the University of Cambridge, Marion developed the world’s first clinically effective oral biologic – a bi-specific VHH engineered for resistance to intestinal proteases.

    Over her 5 years at Isogenica, Marion continues to share her expertise on end-to-end VHH product development, from complex discovery strategies to advanced engineering and novel manufacturing approaches.

    Tommaso Tosi is currently Principal Scientist in the Biochemistry Group at Axxam, with four years of experience in protein purification, biochemical assay development and compound profiling campaigns.

    Tommaso has successfully developed several biochemical assays suitable for high-throughput screening and compound profiling on a wide range of targets, including soluble enzymes, protein-protein and protein-nucleic acid complexes and purified integral membrane proteins.

    Tommaso has a Master’s Degree in Pharmaceutical Biotechnology and a Ph.D. in Structural Biology and Nanobiology, and years of experience in international academia and industry. He is also author and co-author of a number of relevant publications.

    Scroll to Top